Abstract
The aim of this study to design a stable microemulsion formulation to deliver a combination of rifampicin, isoniazid and pyrazinamide in quantities suitable for administration to a paediatric population. The chemical stability of rifampicin, isoniazid and pyrazinamide alone and in various combinations was investigated in different solvents, solubilizing agents and surfactants. An artificial neural network was used to model data from the stability studies and a sensitivity analysis was applied to optimize the selection of the formulation components. Imwitor 308 and Crillet 3, exhibiting the highest overall positive sensitivity were selected to formulate the stable microemulsion. Due to drug dose specifications and solubility limitations, the final formulation contained only rifampicin and isoniazid, since the solubility of pyrazinamide in the lipid and aqueous components of the microemulsion did not achieve the required dose. The stability and solubility of rifampicin were improved in the formulation. Solubilization of the rifampicin in the lipid droplets of the internal phase and lipophilic chains of the surfactants increased the quantity of rifampicin that can be incorporated, while protecting it from oxidative degradation and also limited its contact with isoniazid, which has been shown to affect its stability. The results of this study indicate that the Artificial Neural Network can be successfully used to optimize the choice of solvents, solubilizing agents and surfactants prior to formulation of the microemulsion, limiting the amount of experiments, thus reducing the costs during the preformulation study.
Keywords: fixed-dose combination, paediatric liquid dosage form, microemulsion, artificial neural network (ann), rifampicin, isoniazid, pyrazinamide
Current Drug Discovery Technologies
Title: Artificial Neural Networks to Optimize Formulation Components of a Fixed- Dose Combination of Rifampicin, Isoniazid and Pyrazinamide in a Microemulsion
Volume: 2 Issue: 3
Author(s): B. D. Glass, S. Agatonovic-Kustrin and M. H. Wisch
Affiliation:
Keywords: fixed-dose combination, paediatric liquid dosage form, microemulsion, artificial neural network (ann), rifampicin, isoniazid, pyrazinamide
Abstract: The aim of this study to design a stable microemulsion formulation to deliver a combination of rifampicin, isoniazid and pyrazinamide in quantities suitable for administration to a paediatric population. The chemical stability of rifampicin, isoniazid and pyrazinamide alone and in various combinations was investigated in different solvents, solubilizing agents and surfactants. An artificial neural network was used to model data from the stability studies and a sensitivity analysis was applied to optimize the selection of the formulation components. Imwitor 308 and Crillet 3, exhibiting the highest overall positive sensitivity were selected to formulate the stable microemulsion. Due to drug dose specifications and solubility limitations, the final formulation contained only rifampicin and isoniazid, since the solubility of pyrazinamide in the lipid and aqueous components of the microemulsion did not achieve the required dose. The stability and solubility of rifampicin were improved in the formulation. Solubilization of the rifampicin in the lipid droplets of the internal phase and lipophilic chains of the surfactants increased the quantity of rifampicin that can be incorporated, while protecting it from oxidative degradation and also limited its contact with isoniazid, which has been shown to affect its stability. The results of this study indicate that the Artificial Neural Network can be successfully used to optimize the choice of solvents, solubilizing agents and surfactants prior to formulation of the microemulsion, limiting the amount of experiments, thus reducing the costs during the preformulation study.
Export Options
About this article
Cite this article as:
Glass D. B., Agatonovic-Kustrin S. and Wisch H. M., Artificial Neural Networks to Optimize Formulation Components of a Fixed- Dose Combination of Rifampicin, Isoniazid and Pyrazinamide in a Microemulsion, Current Drug Discovery Technologies 2005; 2 (3) . https://dx.doi.org/10.2174/1570163054866864
DOI https://dx.doi.org/10.2174/1570163054866864 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Slow-Onset Inhibition of 2-trans-Enoyl-ACP (CoA) Reductase from Mycobacterium tuberculosis by an Inorganic Complex
Current Pharmaceutical Design Simultaneous Detection of Drug-resistant Mutations in <i>Mycobacterium tuberculosis</i> and Determining their Role through <i>In Silico</i> Docking
Infectious Disorders - Drug Targets Structure and Mechanism of Arylamine N-Acetyltransferases
Current Topics in Medicinal Chemistry Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry DprE1 - from the Discovery to the Promising Tuberculosis Drug Target
Current Pharmaceutical Design Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone
Drug Metabolism Letters Structure and Regulation of the Drug-Metabolizing Enzymes Arylamine N-acetyltransferases
Current Medicinal Chemistry Editorial: An Emerging Immunogenomics and Computational Approach for Peptide Vaccinology: Rational Design of Peptide Vaccines
Current Computer-Aided Drug Design In Vitro Anti-mycobacterial Activity of Three Medicinal Plants of Lamiaceae Family
Recent Patents on Anti-Infective Drug Discovery α-Glucan Pathway as a Novel Mtb Drug Target: Structural Insights and Cues for Polypharmcological Targeting of GlgB and GlgE
Current Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Synthesis, In Vitro Evaluations and Structure-Activity Assessment of Pyrrole Hydrazones as Potential Tuberculostatics
Letters in Drug Design & Discovery Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Chemoinformatics Approach for Building Molecular Networks from Marine Organisms
Combinatorial Chemistry & High Throughput Screening Anti-infective Potential of Manzamine Alkaloids - A Review
Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents
Infectious Disorders - Drug Targets Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Infrequent Infections in COPD
Current Respiratory Medicine Reviews